A Stanford University spinout that lists Johnson & Johnson, Novartis and Pfizer among its users has raised $10 million to develop its brain mapping…

After rejecting Abbott’s $50 million breakup offer in April, Alere is now suing the devicemaker in a bid to force it to complete the acquisition.

Theranos, which has come under fire over the validity of its fingerprick blood tests, announced Friday that it plans to appeal sanctions served last month by…

Sofinnova Ventures, which over the course of its now ten funds has evolved its focus from early-stage life science and tech firms to later stage biotechs, has…

Medivation loses its VP after the Pfizer buy, Shanghai Pharma loses its chairman after only three months and Sarah Jessica Parker waves goodbye to Mylan…

Belgium biotech argenx has seen its income double on the back of a strong year of deals, but has also seen fit to cut two former R&D pacts.

Struggling microcap GenVec has again been warned that it will be taken off the lucrative and respected Nasdaq exchange if it doesn’t get itself out of the…

Adocia has cut loose its diabetic foot ulcer program after the drug failed a Phase III trial.